Overview

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Hepatocellular Carcinoma

Status:
Recruiting
Trial end date:
2029-05-01
Target enrollment:
Participant gender:
Summary
This is first in human study to evaluate the safety, tolerability, immunogenicity, and preliminary clinical activity of RZ-001 when given to subjects with human telomerase reverse transcriptase (hTERT)-positive HCC.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Rznomics, Inc.